Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin, Walter Colasante, and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
How COVID-19 could revolutionize the UK pharmaceutical procurement landscape: A DOAC procurement case study
Direct oral anticoagulants (DOACs) are widely used pharmaceutical products which represent a significant cost to the healthcare system. In 2021, National...